Depending on the type of alternative payment models, it could be more difficult or easier for practices to find overlaps and participate in multiple models, said Mike Fazio, senior vice president of client services, Archway Health.
Depending on the type of alternative payment models, it could be more difficult or easier for practices to find overlaps and participate in multiple models, said Mike Fazio, senior vice president of client services, Archway Health.
Transcript
As the country moves to value-based care, the number of alternative payment models is growing, and many practices are participating in more than one. Are they having trouble balancing multiple models?
It depends on the model. So, OCM [Oncology Care Model] involves so much of the patient mix of OCM practices and because of the care transformation components of the program from the get-go it’s been an area of focus for anyone that’s in OCM.
In some of the other programs, like BPCI [Bundled Payments for Care Improvement] Advanced, there is intersection and overlap with other programs, like the ACO [accountable care organization] program, for example. And those models, thought, BPCI is a great avenue to incent specialists within a primary care model, like an ACO. So, it does differ.
But from an OCM perspective we see that participants are very focused and with the movement toward downside risk in OCM, for those practices that make that choice this fall, definitely more focus on OCM because of that. Whereas a one-sided model, it’s a different beginning than being in a risk-based model.
Impact of Hospital-Physician Integration on Medicare Patient Mix
April 11th 2025This study found no evidence that hospital employment of physicians resulted in physicians treating sicker patients, undercutting claims that hospital-employed physicians serve a higher-acuity patient mix.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation
April 10th 2025Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.
Read More